SK Bioscience

Fina Biosolutions is a biotechnology company focused on developing and collaborating on innovative vaccine conjugates aimed at preventing life-threatening diseases. The company employs proprietary techniques to conjugate, purify, and manufacture complex vaccine conjugates. By utilizing advanced bioconjugation methods, Fina Biosolutions provides a range of services including protein expression, purification, immunoassay design, analytics, as well as training and consulting. These capabilities not only enhance the accessibility of life-saving vaccines but also work to reduce the associated costs, ensuring that more individuals can benefit from essential vaccination.

Sunflower Therapeutics is a biotechnology company focused on advancing protein manufacturing solutions to enhance global access to biological medicines. By employing strain engineering and integrated process development, the company aims to create efficient, automated systems for protein production. These innovations are designed to support a wide range of applications, including new medicines and food products, allowing clients to significantly reduce the time and costs associated with developing and manufacturing biologics. Sunflower Therapeutics emphasizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations, reflecting its commitment to benefiting the global population.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.